Safety of long‐term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection

Abstract

Among patients with a prHBV infection and rheumatologic indications for long-term biologic therapies, HBV reactivation was not seen; this suggests that universal prophylaxis is not justified and is not cost-effective in this clinical setting.